Biotech | April 25, 2022
Shilpa Medicare receives NoC for biosimilar Aflibercept
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
A separate global Phase 3 study of S-217622 is underway aiming to recruit participants globally to support regulatory filings this year
Under the agreement, Porton Advanced will provide services to accelerate the development, production and registration of breakthrough cell therapies currently being developed by Sinorda Biomedicine
Heavy bleeding after giving birth is globally a leading cause of death in new mothers
Continuation of pediatric expansion in adolescents of PREVENT-19 Phase 3 trial will evaluate safety and immunogenicity of a booster dose
The Phase 3 trial will be conducted under the auspices of the first Regenerative Medicine Advanced Therapy (RMAT) designation approved by the USFDA for an EV therapeutic
Bringing together Bristol Myers Squibb and Celgene on one clinical trial management system, company goes live with Vault CTMS in record speed
The report pointed out that in the process of treating Covid-19, there are promising data to suggest that TCM is beneficial in reducing the risk of progression from mild-to-moderate cases to severe Covid-19
Approval for primary and booster immunization is based on efficacy and safety data from Japan and international clinical studies
The US $600 million acquisition will see Juniper Biologics offer the world's first cell-mediated gene therapy to an estimated 300 million patients in Asia Pacific, Middle East and Africa
Subscribe To Our Newsletter & Stay Updated
